Condition: First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer · Sponsor: Shanghai JMT-Bio Inc.
This is a randomized, controlled, open-label, multicenter, phase Ш clinical study designed to compare the efficacy and safety of KN026 in combination with HB1801 to trastuzumab in combination with pertuzumab and docetaxel in the first-line treatment of subjects with HER2-positive recurrent or metastatic breast cancer. The statistical assumption for this study is superiority. The primary study endpoint was PFS as assessed by Blinded Independ Review Committee (BIRC).
This description comes directly from the study's public registry record.
Clinical Trials Information Group Officer · +86-0311-69085587 · ctr-contact@mail.ecspc.com
fenglin She · 18301190515 · shefenglin@cspc.cn
Always discuss trial participation with your own doctor first.
| Clinical Trials Information Group | Beijing, chaoyang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05838066